TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29672526

Group type: EXPERIMENTAL
Intervention: Multi-faceted handoff intervention (education session, standardized procedures, fixed time and location for handoff)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Multi-faceted handoff intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual non-standardized handoffs (control group)
Number of subjects: 18
Study: 27806235

Group type: EXPERIMENTAL
Intervention: BIA 10‐2474 (50 mg per day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 24496169

Group type: EXPERIMENTAL
Intervention: Combined lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 μg/mL
Number of subjects: 52
Study: 22214842

Group type: EXPERIMENTAL
Intervention: LCn‐3PUFA (fish oil group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (monounsaturated oil group)
Number of subjects: 32
Study: 19859755

Group type: EXPERIMENTAL
Intervention: Manipulation of background exposure to a novel domain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evaluative tasks
Number of subjects: 0
Study: 17417075

Group type: COMPARATOR
Intervention: Halofantrine (HF) 500 mg alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Halofantrine (HF) 500 mg with prior administration of amodiaquine (AQ) 600 mg
Number of subjects: 10
Study: 16311142

Group type: EXPERIMENTAL
Intervention: Olanzapine (20 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Propranolol (120 mg/day)
Number of subjects: 38
Study: 12730556

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10551579

Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 10 microg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intrathecal sufentanil alone (ED50 4.1 +/- 0.31 microg)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil combined with neostigmine 10 microg (ED50 3.0 +/- 0.28 microg)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sufentanil (9 microg)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sufentanil (6 microg) plus neostigmine (10 microg)
Number of subjects: 106
Study: 7551923

Group type: EXPERIMENTAL
Intervention: Polychemotherapy
Number of subjects: 700

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 700
Study: 2025853

Group type: EXPERIMENTAL
Intervention: 4250 cGy in 25 daily fractions for 5 weeks (Group 1)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 4500 cGy in 25 daily fractions for 5 weeks (Group 2)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 5100 cGy in 30 daily fractions for 6 weeks (Group 3)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Intravaginal brachytherapy after whole‐pelvis RT
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Depth of myometrial invasion
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Tumor grade, pathologic stage, whole‐pelvis radiation dose, and the use of brachytherapy
Number of subjects: 86
Study: 6896576

Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30958353

Group type: EXPERIMENTAL
Intervention: D-Cycloserine (DCS) 15 mg BID
Number of subjects: 756

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 756
Study: 29253346

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 180
Study: 26683109

Group type: EXPERIMENTAL
Intervention: TRV130 2 mg q3h
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: TRV130 3 mg q3h
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Morphine 4 mg q4h
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: TRV130 2 mg
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: TRV130 3 mg
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 339
Study: 25253016

Group type: EXPERIMENTAL
Intervention: Allogeneic plasma
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Succinylated gelatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Parkland
Number of subjects: 24
Study: 22395582

Group type: EXPERIMENTAL
Intervention: CT gel (clindamycin phosphate 1.2% and tretinoin 0.025%)
Number of subjects: 1649

Group type: EXPERIMENTAL
Intervention: CT gel
Number of subjects: 1649

Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 1649

Group type: COMPARATOR
Intervention: Tretinoin
Number of subjects: 1649

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 1649
Study: 18469161

Group type: EXPERIMENTAL
Intervention: Glycemic index (GI) and glycemic load (GL) dietary intervention for 9 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Nutrition education regarding GI and GL
Number of subjects: 103
Study: 17449506

Group type: EXPERIMENTAL
Intervention: Dietary sodium reduction for 18 months (TOHP I) or 36-48 months (TOHP II)
Number of subjects: 3126
Study: 15776198

Group type: EXPERIMENTAL
Intervention: 660 nm wavelength red diode laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: 830 nm wavelength infrared diode laser
Number of subjects: 40
Study: 12229939

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery (intervention group)
Number of subjects: 838

Group type: COMPARATOR
Intervention: Control group (no surgical intervention)
Number of subjects: 838
Study: 9585312

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg followed by thiopental 4-6 mg/kg; intubation after 45 s (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg followed by thiopental 4-6 mg/kg; intubation after 60 s (Group 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vecuronium 0.01 mg/kg followed by thiopental and succinylcholine 1.5 mg/kg; intubation after 60 s (Group 3)
Number of subjects: 45
Study: 7892923

Group type: EXPERIMENTAL
Intervention: Free preventive visits to physicians under Medicare waivers
Number of subjects: 4195

Group type: COMPARATOR
Intervention: Control group (no preventive visits)
Number of subjects: 4195
Study: 2514993

Group type: EXPERIMENTAL
Intervention: 18-gauge needle
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 20-gauge needle
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 21-gauge needle
Number of subjects: 152
Study: 72192

Group type: EXPERIMENTAL
Intervention: Oral non-absorbed antibiotics
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 30925280

Group type: EXPERIMENTAL
Intervention: Nurse-led decision coaching with evidence-based decision aid
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 64
Study: 26909662

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 108

Group type: COMPARATOR
Intervention: Nutrition education
Number of subjects: 108

Group type: COMPARATOR
Intervention: Exercise plus nutrition education
Number of subjects: 108
Study: 26035743

Group type: EXPERIMENTAL
Intervention: Withholding breastfeeding (one hour before through one hour after vaccination)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Immediate breastfeeding at the time of vaccination
Number of subjects: 400
Study: 23866300

Group type: EXPERIMENTAL
Intervention: Ziprasidone 20‐160 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olanzapine 5‐20 mg/day
Number of subjects: 20
Study: 21653904

Group type: EXPERIMENTAL
Intervention: Active bupropion SR and 11 sessions of CBT for 40 weeks (A-CBT)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Active bupropion SR for 40 weeks
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Placebo and 11 sessions of CBT for 40 weeks
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo for 40 weeks
Number of subjects: 406

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 406
Study: 19184081

Group type: EXPERIMENTAL
Intervention: latanoprost
Number of subjects: 58

Group type: COMPARATOR
Intervention: dorzolamide/timolol
Number of subjects: 58
Study: 16928196

Group type: EXPERIMENTAL
Intervention: High-intensity treadmill training (TMT), n=7
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CON), n=6
Number of subjects: 18
Study: 15116057

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m²)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Docetaxel (10 mg/m²) with ketoconazole (200 mg once daily for 3 days)
Number of subjects: 7
Study: 11702016

Group type: EXPERIMENTAL
Intervention: 5-HT(6) C267T genetic variant
Number of subjects: 57

Group type: COMPARATOR
Intervention: Antidepressant treatment
Number of subjects: 57
Study: 9453428

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1 g per day orally)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8941543

Group type: EXPERIMENTAL
Intervention: Concentric training (CTG)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Eccentric training (ETG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 54
Study: 2183879

Group type: EXPERIMENTAL
Intervention: Diazepam 0.12 mg/kg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Diazepam 0.20 mg/kg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 6251644

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (INTAL)
Number of subjects: 55
Study: 30629285

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide 10 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 148
Study: 27984250

Group type: EXPERIMENTAL
Intervention: Music group (listened to preferred music)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (listened to no music)
Number of subjects: 100
Study: 25524831

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.42
Number of subjects: 798

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 798
Study: 23438139

Group type: EXPERIMENTAL
Intervention: Vitamin A palmitate and antioxidant-containing oil-based moisturizer
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 0
Study: 21277840

Group type: EXPERIMENTAL
Intervention: Adjusted pulse amplitude TENS
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Fixed pulse amplitude TENS
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study: 19961453

Group type: EXPERIMENTAL
Intervention: MTA stored in normal saline (NS) for 1 week (Group A1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MTA stored in phosphate buffer saline (PBS) for 1 week (Group A2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NEC stored in normal saline (NS) for 1 week (Group B1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NEC stored in phosphate buffer saline (PBS) for 1 week (Group B2)
Number of subjects: 24
Study: 17967711

Group type: EXPERIMENTAL
Intervention: Three-dimensional intravascular ultrasound (IVUS) imaging
Number of subjects: 88

Group type: COMPARATOR
Intervention: Quantitative cineangiographic analysis (QCA)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetic patients
Number of subjects: 88

Group type: COMPARATOR
Intervention: Non-insulin-treated diabetic patients
Number of subjects: 88
Study: 15136070

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11230834

Group type: EXPERIMENTAL
Intervention: Eptifibatide with heparin
Number of subjects: 6977

Group type: COMPARATOR
Intervention: Placebo with heparin
Number of subjects: 6977

Group type: EXPERIMENTAL
Intervention: Eptifibatide without heparin
Number of subjects: 6977

Group type: COMPARATOR
Intervention: Placebo without heparin
Number of subjects: 6977

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 6977

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 6977
Study: 8963818

Group type: EXPERIMENTAL
Intervention: 6.00-mm diameter zones
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5.00-mm zones
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5.00- to 6.00-mm multizone treatment
Number of subjects: 60
Study: 1465561

Group type: EXPERIMENTAL
Intervention: Duraphat
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Vitrabond
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Retreatment of Duraphat failures with Vitrabond
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Retreatment of Vitrabond failures with Duraphat
Number of subjects: 112
Study: 6608581

Group type: EXPERIMENTAL
Intervention: Moxalactam (200 mg/kg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ampicillin (400 mg/kg/day) plus chloramphenicol (75 mg/kg/day)
Number of subjects: 34
Study: 30642194

Group type: EXPERIMENTAL
Intervention: Home assessment visit by an occupational therapist prior to discharge
Number of subjects: 77
Study: 29218680

Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/day
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/day
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Valbenazine (both dosages)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Valbenazine (up to 48 weeks)
Number of subjects: 400
Study: 26307133

Group type: EXPERIMENTAL
Intervention: CPS therapy (Carboplatin, Paclitaxel, and Sorafenib)
Number of subjects: 119

Group type: COMPARATOR
Intervention: CP therapy (Carboplatin and Paclitaxel)
Number of subjects: 119
Study: 24481213

Group type: EXPERIMENTAL
Intervention: Visit-to-visit SBP variability (highest decile)
Number of subjects: 5880
Study: 22178164

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound-guided embryo aspiration plus local administration of low-dose methotrexate (MTX)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Systemic administration of MTX plus curettage with hysteroscopy (control group)
Number of subjects: 68
Study: 21146010

Group type: EXPERIMENTAL
Intervention: Single dose of antibiotics during CVAP placement
Number of subjects: 459

Group type: COMPARATOR
Intervention: No antibiotics during CVAP placement
Number of subjects: 459
Study: 17096683

Group type: EXPERIMENTAL
Intervention: Quinidine (4 mg kg(‐1) infusion for 20 min)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 37
Study: 16076867

Group type: EXPERIMENTAL
Intervention: NPM1 mutations
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: NPM1+/FLT3‐LM‐ mutations
Number of subjects: 401

Group type: COMPARATOR
Intervention: NPM1+/FLT3‐LM+
Number of subjects: 401
Study: 12000813

Group type: EXPERIMENTAL
Intervention: Immediate surgical repair of the aneurysm
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Surveillance (ultrasonography or CT every six months)
Number of subjects: 1136
Study: 10533479

Group type: EXPERIMENTAL
Intervention: Third intensification block of chemotherapy (including dexamethasone)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuing chemotherapy
Number of subjects: 18
Study: 7762325

Group type: EXPERIMENTAL
Intervention: Suppressive therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonsuppressed nodules
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Repeat FNA (with or without suppressive therapy)
Number of subjects: 28
Study: 2025190

Group type: EXPERIMENTAL
Intervention: Continuous subcuticular non-absorbable polypropylene 'prolene' suture
Number of subjects: 66

Group type: COMPARATOR
Intervention: Metal skin staples
Number of subjects: 66

Group type: COMPARATOR
Intervention: Metal skin staples (removed at 10 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Metal skin staples (removed at 14 days)
Number of subjects: 66
Study: 7027890

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 52
Study: 31553438

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day orally)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2 intravenously) plus Docetaxel (60 mg/m2 i.v.)
Number of subjects: 172
Study: 28318455

Group type: EXPERIMENTAL
Intervention: GlideScope Ranger video laryngoscope
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope
Number of subjects: 20
Study: 26837508

Group type: EXPERIMENTAL
Intervention: Lateral osteotomy following tip plasty
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lateral osteotomy before tip plasty
Number of subjects: 65
Study: 24313636

Group type: EXPERIMENTAL
Intervention: Propess (intact membranes)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Propess (natural rupture)
Number of subjects: 169
Study: 22128294

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 µg vaginally) after 200 mg mifepristone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 20
Study: 19243721

Group type: EXPERIMENTAL
Intervention: Spinal manipulation of the atlanto-occipital joint
Number of subjects: 37

Group type: COMPARATOR
Intervention: Manual contact placebo intervention (Control)
Number of subjects: 37
Study: 17576325

Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg ketoconazole
Number of subjects: 90

Group type: COMPARATOR
Intervention: Two doses of 300 mg fluconazole with 2 weeks interval
Number of subjects: 90
Study: 15168391

Group type: EXPERIMENTAL
Intervention: MMF (1,000 mg) + Ferrous sulfate (105 mg) coadministered
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MMF (1,000 mg) + Ferrous sulfate (4 hours later)
Number of subjects: 10

Group type: COMPARATOR
Intervention: MMF (1,000 mg) alone (control)
Number of subjects: 10
Study: 11452246

Group type: EXPERIMENTAL
Intervention: Morphine 0.4 mg, 1.2 mg, and 3.6 mg administered intraligamentarily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine 1.2 mg administered subcutaneously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine 1.2 mg and Fentanyl 50 microg administered submucosally
Number of subjects: 0
Study: 9570649

Group type: EXPERIMENTAL
Intervention: S. boulardii 113 g twice daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 7799581

Group type: EXPERIMENTAL
Intervention: Combined endolymphatic therapy (lymph irradiation with helium-neon laser and direct endolymphatic antibacterial therapy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 3207542

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31455324

Group type: EXPERIMENTAL
Intervention: Mobile outreach team treatment (DOTS regime)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Facility-based DOTS treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mobile outreach team treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (Mobile outreach and Facility-based)
Number of subjects: 200
Study: 28458075

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 255

Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 255

Group type: COMPARATOR
Intervention: Brief Advice to quit
Number of subjects: 255
Study: 26243363

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (HiPRT) with impact loading (n=12)
Number of subjects: 28
Study: 22747323

Group type: EXPERIMENTAL
Intervention: RRGI (deep breathing, relaxation response, meditation, and guided imagery techniques)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CB (cognitive behavioral techniques)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RRGICB (combination of RRGI and CB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 21309489

Group type: EXPERIMENTAL
Intervention: Remifentanil at target effect-site concentration (Ce) of 0.5 ng/ml
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Remifentanil at target effect-site concentration (Ce) of 1 ng/ml
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Remifentanil at target effect-site concentration (Ce) of 2 ng/ml
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Remifentanil at target effect-site concentration (Ce) of 4 ng/ml
Number of subjects: 104
Study: 17635940

Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (0.4 nmol/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 15618248

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 0
Study: 11856794

Group type: EXPERIMENTAL
Intervention: Hypothermia (core body temperature reduced to 33 degrees C within 2 hours and maintained for 12 hours)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 77
Study: 10542978

Group type: EXPERIMENTAL
Intervention: Calibration with a 3000 ml syringe
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Spirometer A
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Spirometer B
Number of subjects: 43

Group type: COMPARATOR
Intervention: Comparison with gold standard (CDS)
Number of subjects: 43
Study: 7887841

Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 1.0% apraclonidine
Number of subjects: 129
Study: 2240297

Group type: EXPERIMENTAL
Intervention: Food Behavior Checklist (FBC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Introductory items as memory retrieval cues
Number of subjects: 96
Study: 106982

Group type: EXPERIMENTAL
Intervention: 5 antiinflammatory drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30428049

Group type: EXPERIMENTAL
Intervention: Pimodivir 300 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg plus Oseltamivir 75 mg
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 30305657

Group type: EXPERIMENTAL
Intervention: dp‐ucMGP (desphospho‐uncarboxylated matrix Gla protein)
Number of subjects: 935
Study: 26739013

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 194

Group type: COMPARATOR
Intervention: Conventional antihypertensive medication
Number of subjects: 194